VOA慢速英语2020 礼来公司寻求实验性新冠肺炎抗体药物获批（在线收听）

Drug maker Eli Lilly and Company said Wednesday it has asked U.S. officials to approve emergency use of an experimental antibody treatment for COVID-19.

制药商礼来公司周三表示，其已请求美国官员批准紧急使用一种针对新冠肺炎的实验性抗体疗法。

Lilly said early results of a study show the treatment reduced hospital emergency room visits for persons with mild or moderate forms of COVID-19. It said the therapy also reduced signs of the disease, the amount of the virus and length of hospital stays for such patients.

礼来表示，一项研究的早期结果显示，这种疗法减少了轻度或中度新冠肺炎患者的医院急诊就诊量。该公司表示，这种疗法还减少了新冠肺炎症状、病毒数量以及患者住院的时间。

The company announced the study's partial results before a meeting with investors and the public. The findings have yet to be published or examined by independent scientists.

礼来公司在与投资者和公众见面前宣布了部分研究结果。这些发现尚未公开或由独立科学家进行检验。

The antibody treatment appears to work like one given to President Donald Trump last Friday. The treatment he took was developed by Regeneron Pharmaceuticals.

就效果而言，抗体疗法似乎与上周五特朗普总统接受的疗法类似。总统接受的疗法由瑞格龙制药公司开发。

Both therapies are designed to connect human antibodies to the coronavirus that causes COVID-19 and limit its ability to spread. The antibodies are usually given as a one-time treatment through intravenous therapy.

这两种疗法都是为了将人类抗体与引起新冠肺炎的冠状病毒联系起来，并限制其传播能力。一般来说，抗体是经由静脉注射进行的一次性疗法。

Daniel Skovronsky is a doctor and Eli Lilly's chief scientific officer. He said in a statement, "We believe the data generated to date provide sufficient evidence that both monotherapy and combination therapy may be effective to treat COVID-19 in patients with a high risk for serious outcomes."

丹尼尔·科科夫斯基是一名医生，也是礼来公司的首席科学官。他在一份声明中表示，“我们相信迄今为止的数据提供了足够的证据，证明单一疗法和联合疗法可能对治疗具有严重后果风险的患者有效。”

The monotherapy involves an antibody called LY-CoV555. The combination therapy combines that antibody with an antibody called LY-CoV016.

单一疗法涉及一种名为LY-CoV555的抗体。而联合疗法则将这种抗体与名为LY-CoV016的抗体结合起来。

The medical news website StatNews reported that "Lilly had previously released results for a similar treatment using one antibody, which experts viewed as promising. But the new results, of a combination of two antibodies, appear, based on limited data provided in a press release, to be more robust."

医学新闻网站StatNews报道称，“礼来公司此前发布了使用一种抗体进行类似治疗的结果，专家认为存在希望。但根据新闻稿中提供的有限数据，由两种抗体组合而成的新结果似乎更加可靠。”

The drug maker is asking the U.S. Food and Drug Administration (FDA) to permit use of its single antibody treatment in emergency situations. The company expects to seek government approval of the combination treatment in November.

礼来公司请求美国食品药品监督管理局（简称FDA）允许在紧急情况下使用其单一抗体疗法。该公司将在11月就联合疗法寻求政府批准。

At this time, the FDA has only approved the drug remdesivir for emergency use in COVID-19 patients. The president's personal doctor confirmed that Trump has also started a five-day treatment of remdesivir.

目前，美国食药监局只批准了瑞德西韦用于新冠肺炎患者的紧急治疗。总统的私人医生证实，特朗普也已开始进行为期5天的瑞德西韦治疗。

Lilly said it has already started manufacturing the drug LY-CoV555. The company expects to have 100,000 doses ready in October and 1 million by the end of the year. It hopes to have 50,000 doses of the combination therapy ready by year's end.

礼来公司表示，他们已经开始生产药物LY-CoV555。该公司预计10月份将有10万剂疫苗准备就绪，到今年年底将达到100万剂。礼来公司希望在年底前有5万剂联合疗法疫苗。

The drug maker added that it is also "working with regulators around the world to make these treatments available."

制药公司礼来补充称，其还“在与世界各地的监管机构合作，目标是使这些疗法成为可能。”

Words in This Story

intravenous - adj. through a vein

monotherapy - n. the use of a single drug to treat a disease or condition

outcome - n. something that happens as a result of an activity or process

view - v. to think about something in a particular way

robust - adj. strongly formed

dose - n. the amount of medicine

regulator - n. a government official who controls the public activity by making and enforcing rules